Finally, our data show that JAK2‐targeting and BRD4/MYC‐targeting drugs counteract the IFN‐γ‐induced expression of PD‐L1 on MPN cells and MPN NSC. This evidence concerns the gene BRD4 and myeloproliferative disorder.